FGL
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
FGL is a specialist neuroplasticity peptide for researchers focused on memory consolidation, LTP enhancement, and neuroprotection, not a general productivity nootropic.
The main hard stop is simultaneous Dihexa use; keep FGL sequential and separated, not stacked.
FGL is a specialist neuroplasticity peptide for researchers focused on memory consolidation, LTP enhancement, and neuroprotection, not a general productivity nootropic.
Do not combine with Dihexa; community harm-reduction consensus flags possible apoptosis from overlapping pro-synaptogenic pressure. Human efficacy data is absent, long-term effects are unknown, sourcing is difficult, and dose references span mcg-scale SC use versus mg-scale intranasal Phase I safety data.
FGL's appeal is its unusually specific NCAM-FGFR1 mechanism: activity-dependent LTP enhancement that nearly doubled memory-encoding signals in preclinical preparations, with Phase I intranasal safety data but no human efficacy readout.
Preclinical efficacy is stronger than the human evidence. One documented 250 mcg twice-daily SC report over about 10 days described easier learning and mood lift, but broader claims about dramatic AMPA-density enhancement remain anecdotal and unverified.
Never use FGL and Dihexa at the same time; wait until Dihexa is fully cleared before starting FGL.
Intro
FGL is a synthetic 15-amino acid neuropeptide (sequence: EVYVVAENQQGKSKA) derived from the fibroblast growth loop region of neural cell adhesion molecule (NCAM).
NCAM is a cell surface glycoprotein expressed on virtually all neural cells that plays a central role in neural development, differentiation, synaptic plasticity, and memory formation. FGL specifically mimics the region of NCAM that binds to fibroblast growth factor receptor 1 (FGFR1), making it an FGFR agonist that activates the NCAM-FGFR signaling pathway without requiring full-length NCAM protein.
Its molecular weight is approximately 1,500 Da, placing it among the smaller neuropeptides. Half-life has not been well characterized in humans. Variants include FGL(L) (the L-amino acid form used in human clinical trials), FGL-S (a sulfated/stabilized variant with enhanced bioavailability), and HA-FGL (a hyaluronate conjugate with different pharmacokinetics — extremely rare and not commercially available).
FGL has been in clinical development for neurodegenerative diseases. An 8-day Phase I trial in 24 healthy male volunteers (ages 24-55) confirmed safety and acceptable dose-related pharmacokinetics for intranasal FGL(L) at single doses of 25, 100, and 200 mg. No serious adverse events were reported. This established the safety foundation, but no Phase II or III trials have reported efficacy outcomes in cognitive enhancement or disease treatment. The compound is currently in pre-Phase II status for Alzheimer's disease, stroke, and TBI applications.
In the research community, FGL is framed as a compound that may help encode information more efficiently by heightening synaptic plasticity specifically in response to activity — not by producing indiscriminate synaptic enhancement. This activity-dependent mechanism is considered its key safety feature, distinguishing it from compounds that might produce uncontrolled neuronal excitation.
Observed Effects
Preclinical evidence for FGL's cognitive effects is concentrated in rodent models and in vitro hippocampal slice preparations.
In animal studies, FGL administered intracerebroventricularly improved both spatial memory (water maze task) and associative memory (fear conditioning task). Memory benefits appeared 24 hours after training and persisted for 14 days in the spatial learning task and 28 days in the fear conditioning task, suggesting that FGL primarily affects memory consolidation processes in the hippocampus rather than acquisition or retrieval alone.
In hippocampal slice preparations, electrical stimulation of FGL-treated tissue induced LTP nearly twice as strongly as in untreated slices. This effect was NMDA receptor-dependent — blocking NMDA receptors eliminated FGL's enhancement of AMPA receptor delivery to synapses, confirming the gating mechanism. Crucially, this LTP enhancement occurs only in response to synaptic activity, not spontaneously, which is considered the basis for its favorable safety profile.
Beyond cognitive effects, FGL shows neuroprotective properties in animal models of ischemic stroke (reduced infarct volume and improved functional outcomes), Alzheimer's disease (protection against amyloid-beta-induced damage), and excitotoxicity. Aged rat studies showed significant ultrastructural changes in dendritic spines and synapses, suggesting structural remodeling that may underlie its utility for age-related cognitive decline rather than only acute enhancement.
In humans, only safety data exists. The single documented first-person community report used 250 mcg twice daily by subcutaneous injection for approximately 10 days and described enhanced learning ease and a definite mood lift. A second community report described potent cognitive effects with AMPA receptor enhancement, but provided no specifics. These reports are consistent with the expected mechanistic effects but cannot be independently verified.
Field Reports
First-person experience data for FGL is extremely thin relative to even moderately well-studied nootropic peptides.
The one detailed report used 250 mcg twice daily by subcutaneous injection for approximately 10 days and described easier learning, definite mood lift, and a subjective sense of increased mental plasticity. It did not include bloodwork, standardized cognitive tests, or follow-up timeline data.
A second anecdotal report described FGL as very potent and connected the effect to AMPA receptor density, but it provided no dose, route, timing, duration, or follow-up. Treat it as a signal that shaped community interest, not as protocol evidence.
No documented adverse experience reports exist from actual FGL use. The apoptosis warning around Dihexa co-administration is a theoretical harm-reduction concern derived from mechanistic reasoning, not a reported adverse event.
The gap between FGL's mechanistic promise, Phase I safety data, and minimal community experience is the core read. This is first-generation territory: no established dose optimization, no documented adverse-event profile, and no community-validated protocol base.
Community Consensus
FGL's community consensus is small, technical, and split between mechanism enthusiasm and practical skepticism.
The positive camp focuses on NCAM-FGFR1 signaling, activity-dependent LTP, and one detailed 2013 self-experiment using 250 mcg twice daily by subcutaneous injection for about 10 days. That report described easier learning and mood lift, but it did not include bloodwork, standardized cognitive testing, or follow-up data.
The skeptical camp is not dismissing the biology; it is reacting to the lack of repeatable human protocols. Later discussion compared FGL to Dihexa and produced the article's strongest practical warning: do not use FGL and Dihexa simultaneously, because overlapping pro-synaptogenic pressure may create apoptosis risk. This warning is not backed by a published adverse-event case, but it is the clearest harm-reduction consensus in the community record.
Sourcing keeps adoption tiny. FGL has been described as harder to find than Dihexa, HA-FGL group-buy attempts did not translate into accessible supply, and clinical-range intranasal dosing would be cost-prohibitive for most users. That pushed discussion toward much lower SC doses, but those doses are community-derived and not validated against the Phase I intranasal safety range.
Broader performance-peptide media has begun mentioning FGL, which may increase awareness. That does not change the evidence base: FGL remains a niche research peptide with interesting preclinical signals, Phase I safety data, and almost no human efficacy texture.
Risks & Monitoring
No serious adverse events were reported in the Phase I human trial of intranasal FGL(L) at 25-200 mg single doses. Transient nasal irritation was the primary adverse event at intranasal doses. Animal studies report good tolerability with no significant systemic toxicity.
The most significant safety concern flagged by the community is the combination of FGL with Dihexa. A later community warning stated that simultaneous use of FGL and Dihexa may cause apoptosis, and that users should wait until Dihexa is completely cleared from the system before starting FGL. The proposed mechanism is overstimulation of synaptogenic pathways: both compounds are potently pro-synaptic, and their simultaneous use may push neuronal plasticity machinery past a survival threshold. This warning lacks published mechanistic support but represents the community's harm-reduction consensus and should be taken seriously given both compounds' potency.
Long-term effects in humans are unknown. Given FGL's role in neuronal growth and plasticity, there are theoretical concerns about indiscriminate synaptogenesis in inappropriate contexts, though the activity-dependent gating mechanism described in preclinical work is intended to limit this risk. There is no community data on tolerance development, which one source claimed was absent based on undisclosed company in-house studies — this remains unverified.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
No established lab-monitoring protocol exists for FGL. Baseline cognitive testing and general health context help interpret response, but this is not a biomarker safety gate.
Repeatable memory or attention tasks, plus mood and learning-ease notes, are the only practical way to judge whether effects match the memory-consolidation mechanism.
Repeating the same cognitive and mood tracking 2-4 weeks after stopping helps separate persistent effects from novelty, practice effects, or transient mood change.
Avoid With
Do not combine FGL with the following. Sorted highest-severity first.
Why:Both FGL and Dihexa are potently pro-synaptogenic compounds. Simultaneous use is hypothesized to overstimulate neuronal plasticity machinery past a survival threshold, potentially causing apoptotic cell death. The mechanism has not been published in peer-reviewed literature but represents the harm-reduction consensus of the FGL community.
What to do:Do not use simultaneously. If researching both, complete one compound's cycle, allow full clearance (given Dihexa's extended duration, this may require 1-2 weeks or more), then begin the other.
Protocols By Goal
Given the absence of human efficacy data, goal-specific protocols cannot be validated. The following reflects mechanistic reasoning and community-sourced framework.
Cognitive enhancement and memory consolidation: Begin at 250 mcg SC once or twice daily, matching the only detailed community reference. Administer before learning-intensive activity to leverage the activity-dependent LTP mechanism — FGL potentiates synaptic plasticity in response to activity, not spontaneously, so the presence of cognitive engagement during the dosing window may maximize benefit. Track learning ease, recall, and mood subjectively over a 4-week cycle.
Neurodegenerative disease research context: Clinical development is targeting higher doses via intranasal route. Individuals researching FGL for this context should follow the Phase I safety window (25-200 mg intranasal) and recognize this is investigational territory without established efficacy protocols.
Neuroinflammation reduction: The IL-4/CD200 anti-inflammatory pathway is secondary to the primary synaptic mechanism. Synergistic potential with other anti-neuroinflammatory compounds (Selank, BPC-157 for systemic inflammation) has been suggested but not tested.
Note: FGL should not be used simultaneously with Dihexa regardless of goal. If both are of interest, run one compound, allow full clearance, then consider the other.
Dosing Details
FGL has no established human dosing protocol for cognitive enhancement. The following reflects what is known from the Phase I trial and community sources, with significant uncertainty acknowledged.
Phase I clinical range (intranasal, safety only): 25-200 mg as a single dose. This range was confirmed safe in the 8-day trial, but the trial did not measure cognitive endpoints, so it does not establish an effective nootropic dose.
Community subcutaneous reference: 250 mcg once or twice daily appears in the only detailed user report, with results noted by day 10. This is field context, not a validated protocol, and it has not been replicated by other documented users.
Alternative intranasal community estimates span roughly 500 mcg-1 mg per dose, far below the Phase I safety range. The spread between mcg-scale community use and mg-scale clinical safety testing is the main dose-confusion problem.
Cycle length is usually discussed as 4-8 weeks followed by assessment, but whether cycling is necessary or beneficial is unknown. Handling, reconstitution, and storage details are sterile-preparation operations and should not be copied as casual home instructions.
Stacks & Alternatives
Semax and Selank act through ACTH-derived and tofisopam-adjacent mechanisms distinct from FGFR1 agonism, potentially providing complementary cognitive and anxiolytic effects. Intranasal administration is compatible for both. This is the most commonly discussed FGL combination in community sources. Do not mix in the same vial; separate peptides can degrade or interact unpredictably when combined before administration.
Cerebrolysin (a polypeptide complex from pig brain cortex) provides a broad neurotrophic factor profile. FGL provides targeted FGFR1 agonism. Both sit in the injectable neurotrophic nootropic lane, which makes the pairing conceptually natural for researchers comfortable with injectable protocols. Neither compound has established human cognitive efficacy data. The combination amplifies both benefit uncertainty and unknown interaction risk.
Both FGL and Dihexa are described as potently synaptogenic. The community's working hypothesis is that they complement each other mechanistically when used sequentially. FGL potentiates existing synaptic connections via LTP; Dihexa is associated with synaptogenesis. Wait for full Dihexa clearance before starting FGL. CRITICAL: Simultaneous use may cause apoptosis per community safety consensus. This is not a standard stack — run one compound, wait, then consider the other only if the first cycle was well-tolerated.
Alternatives
Stack Cost
Specialist stack tax: FGL has no endocrine or organ-load burden, but its Dihexa redline, extreme sourcing difficulty, dose uncertainty, and first-generation neuroplasticity mechanism make it a scarce research slot rather than a casual nootropic add-on.
The article's central safety constraint is a hard no-simultaneous-use warning with Dihexa due to community concern about neuronal apoptosis from overlapping synaptogenic pressure. Any stack containing potent plasticity or excitatory compounds inherits this specialist interaction review.
The article describes FGL as harder to source than Dihexa, extremely expensive at Phase I intranasal doses, and supported by only a tiny community base. Sourcing and affordability dominate practical capacity.
FGL's intended effect is activity-dependent LTP enhancement through NCAM-FGFR signaling. That is the value proposition, but it also means cognitive workload, mood response, sleep quality, and co-use with other CNS-active compounds matter more than they would for a peripheral peptide.
No biomarker panel is established, but the article calls for baseline neurological/cognitive documentation, midcycle tracking, and post-cycle follow-up because human efficacy and long-term safety data are thin.
The practical community protocol is SC at mcg-scale doses while the Phase I safety data used intranasal mg-scale dosing. The injection burden is not large, but route and dose extrapolation create planning risk.
- ·Never run FGL at the same time as Dihexa; sequence them only after a full washout and only if the first compound was tolerated.
- ·Do not combine casually with other strong synaptogenic, AMPAergic, NMDA-modulating, or excitatory nootropic compounds.
- ·Treat dose sources skeptically because the article documents a mcg SC community protocol and a mg intranasal Phase I safety range that are not interchangeable.
- ·Use FGL only when the research question is NCAM-FGFR plasticity, memory consolidation, or neuroprotection; use better-established nootropics for broad cognitive experimentation.
- ·Pair dosing windows with actual learning or rehabilitation work if using it for memory/plasticity, because the article's mechanism is activity-dependent rather than indiscriminate stimulation.
- ·Creates a documentation requirement: baseline cognitive tasks, mood/sleep notes, learning workload log, and post-cycle follow-up.
- ·Creates a sequencing requirement around Dihexa and other potent neuroplasticity agents.
- ·Creates a sourcing verification requirement because FGL supply is rare and route/dose confusion is a major practical hazard.
- ·Creates no HPG, hepatic, lipid, or hematocrit support stack.
The article labels FGL advanced and describes very limited human efficacy data, no established dosing protocol, extreme sourcing difficulty, and a critical Dihexa redline. That pushes it beyond normal beginner or intermediate nootropic use.
- ·The user has not already worked with simpler nootropic or neuropeptide protocols
- ·The goal is general productivity, mood lift, or a Limitless-style experiment
- ·The user cannot maintain a strict no-Dihexa overlap rule
- ·The user is relying on a single product-source dose chart without triangulating route, variant, and units
There is no known withdrawal, suppression, or taper requirement, but long-term human effects and persistence of plasticity changes are unknown. Off-ramp confidence is limited by sparse follow-up data, not by a known recovery syndrome.
- ·Difficulty distinguishing true cognitive changes from novelty, training effect, or mood lift
- ·Unclear persistence window for any benefit or adverse cognitive change
- ·Wasted material or uncertain stability if reconstituted supply remains unused
Do not co-administer. If both compounds are being researched, run one, stop, allow a conservative washout, document baseline return, then consider the other.
Treat route, variant, and units as separate variables. Start from the most conservative route-specific reference and do not convert intranasal mg data directly into SC dosing.
Keep claims limited to the article's evidence: preclinical efficacy, Phase I safety, and minimal community experience. Require endpoint tracking before judging response.
Reject weak sourcing. FGL is rare enough that source quality and identity verification are part of the safety protocol, not an optional purchasing detail.
The article treats this as the critical harm-reduction redline because overlapping pro-synaptogenic pressure may create apoptosis risk.
FGL directly targets synaptic plasticity and CNS signaling; the article has no human safety base for unstable neuropsychiatric populations.
The article's womenConsiderations block makes pregnancy contraindicated by precaution because neurotrophic activity has no pregnancy/lactation safety base.
The article identifies dose confusion across mcg SC and mg intranasal ranges as a major practical hazard.
Practical Setup
Sourcing is the primary practical barrier. FGL is significantly rarer than comparable nootropic neuropeptides (Semax, Selank, Dihexa), and supply consistency is a major practical limitation. The HA-FGL conjugate variant is essentially unavailable through any commercial channel.
Dose confusion is a significant practical hazard. Community sources span a ~1,000-fold dose range, from low mcg-scale SC references to 25-200 mg intranasal Phase I safety dosing. This discrepancy likely reflects different administration routes, different variants (FGL vs FGL-S vs FGL(L)), and uncertain mg-vs-mcg conventions across community sites. Treat any single dose recommendation skeptically and triangulate the 250 mcg twice-daily SC community reference, the Phase I intranasal range, and tolerance tracking rather than converting routes directly.
Lifestyle synergies: Aerobic exercise increases endogenous BDNF, which shares upstream pathway connections with FGL's FGFR1 mechanism. FGL-enhanced LTP benefits memory consolidation processes in the hippocampus — 7-9 hours of quality sleep during a cycle is therefore particularly important, as sleep is the primary window for memory consolidation. Neuroprotective diet (polyphenols, omega-3s, reduced neuroinflammatory load) supports the peptide's anti-inflammatory secondary mechanism.
The Dihexa interaction remains the only clearly established safety constraint. Allow full Dihexa washout before starting FGL. Given Dihexa's pharmacology, this may require several weeks. No other specific interaction concerns have been identified, but given the novelty of both compounds, caution about combining with other potent synaptogenic or excitatory compounds is warranted.
Anyone researching FGL should document baseline cognitive function before beginning, maintain conservative dose assumptions given the data gaps, and approach it as genuine research rather than an established nootropic protocol.
Mechanism Deep Dive
FGL acts as an FGFR1 agonist. Its 15-amino acid sequence (EVYVVAENQQGKSKA) corresponds to the region of NCAM's second fibronectin type III module that forms the binding interface between NCAM and FGFR1.
By directly binding FGFR1, FGL mimics the NCAM-FGFR interaction that occurs naturally during neural development and activity-dependent plasticity.
Binding triggers FGFR1 autophosphorylation via receptor dimerization, activating two primary downstream cascades: MAPK/ERK (driving synaptic plasticity, neurogenesis, and neurite outgrowth) and PI3K/Akt (driving neuroprotection and neuronal survival). These pathways promote: long-term potentiation (LTP) enhancement in the hippocampus and dentate gyrus; hippocampal neurogenesis; axonal regeneration; synaptic spine formation (spinogenesis); and BDNF upregulation.
The critical mechanistic feature is activity dependence. FGL does not spontaneously enhance synaptic transmission — it facilitates LTP only in response to existing synaptic activity. The mechanism requires NMDA receptor activation: when NMDA receptors are blocked, FGL can no longer drive AMPA receptor delivery to synapses. This NMDA-gating creates a coincidence detector: FGL potentiates only synapses that are already active, encoding information more efficiently without creating non-specific excitatory noise. This is the basis for the claim that FGL reduces seizure risk relative to compounds that non-selectively potentiate synaptic transmission.
Secondary anti-inflammatory mechanism: FGL stimulates IL-4 secretion from glial cells, which suppresses microglial activation and reduces IL-1β production. This CD200/IL-4 pathway provides an anti-neuroinflammatory effect that is distinct from the primary synaptic plasticity mechanism and may be relevant to neuroinflammatory conditions and age-related cognitive decline contexts.
FGL also activates FGFR2, though most mechanistic characterization is focused on the FGFR1 pathway. The FGLL/HA-FGL conjugate variant specifically activates NCAM-FGFR pathways for neurite outgrowth and neuronal survival through a modified pharmacokinetic profile.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
FGL-treated hippocampal slices showed LTP nearly twice as strong as untreated slices after electrical stimulation
Mechanistic review and community sources cite this as the hallmark finding driving FGL interest. Not directly translatable to human in vivo dosing.
FGL improved spatial memory (14 days persistence) and fear conditioning memory (28 days persistence) in rodents
ICV route in rodents is not a practical human administration route. SC and intranasal human data is absent for cognitive endpoints. Memory consolidation hypothesis favored over retrieval-only effects.
Phase I intranasal FGL(L) at 25, 100, and 200 mg single doses was well tolerated with no safety concerns and dose-related pharmacokinetic profile in 24 healthy males
8-day study. Established safety window for intranasal delivery. Did not assess cognitive efficacy. CSF concentration measurements confirmed brain penetration at tested doses. Referenced by community sources citing PubMed abstract.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.